Just days after Sanofi CEO Olivier Brandicourt proudly showed off the pharma giant’s return to growth with the stellar performance of Dupixent leading the way, the French company and its longtime allies at Regeneron laid claim to a fresh coup for the franchise, gaining a priority review designation at the FDA for expanding the drug’s reach to adolescents with moderate to severe atopic dermatitis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,